The chapter explores a microcap biotech company's focus on developing therapies for ALS and Alzheimer's disease by targeting inflammatory pathways. It discusses the company's recent investment, expansion into frontotemporal dementia research, and the unique approach involving anti-inflammatory mechanisms. The conversation delves into the challenges of treating these diseases and the promising potential of their therapies on disease progression.
Vention CEO Etienne Lacroix discusses how manufacturers are embracing AI and robotics when it comes to factory innovation. Howard Berman, Chairman and CEO of Coya Therapeutics breaks down a new approach to curing ALS. And we Drive to the Close with Lamar Villere, Portfolio Manager at Villere & Co.
Hosts: Carol Massar & Tim Stenovec Producer: Sara Livezey
See omnystudio.com/listener for privacy information.